These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29365053)

  • 41. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
    Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
    J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.
    Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM;
    J Alzheimers Dis; 2015; 47(3):729-40. PubMed ID: 26401707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
    Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
    J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting future rates of tau accumulation on PET.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease.
    Desikan RS; Cabral HJ; Hess CP; Dillon WP; Glastonbury CM; Weiner MW; Schmansky NJ; Greve DN; Salat DH; Buckner RL; Fischl B;
    Brain; 2009 Aug; 132(Pt 8):2048-57. PubMed ID: 19460794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort.
    Chen Y; Denny KG; Harvey D; Farias ST; Mungas D; DeCarli C; Beckett L
    Alzheimers Dement; 2017 Apr; 13(4):399-405. PubMed ID: 27590706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.